Privi Speciality Chemicals Ltd Q3 FY2026 Concall Summary

Key Takeaways

• 24% revenue, 37% EBITDA growth in a subdued market: Q3 and 9M both delivered 24% YoY revenue growth, while EBITDA jumped 37% YoY in Q3 and 47% in 9M, with margins holding near 25% for the third straight quarter.
• INR5,000 crore vision on track, backed by INR1,200 crore capex: Phase 1 expansion reaches 54,000 metric tons by April '26; Phase 2, the bulk of the spend, completes by Q1 FY27; Phase 3 follows, all funded without equity dilution.
• Prigiv JV turns the corner: The Givaudan joint venture achieved positive EBITDA this quarter, secured a noninterest-bearing trade advance to cut debt costs, and is expected to reach net profit next financial year.
• Bio-route molecules open a new front: Cyclopentanone manufactured via a renewable bio-route for the first time, with a 10x scale-up to 5,000 tons planned in two years and a "10,000 story" promised before the 5,000 milestone is even reached.
• What to watch next quarter: Phase 1 commercialization by April, the merger timeline with NCLT (order expected by October-December '26), and any clarity on whether the ~7% or 11-15% volume growth view for FY27 proves closer to reality.

Financial Performance

• Top-line momentum sustained: 24% YoY revenue growth in both Q3 and 9M FY26, achieved despite a subdued global market. The quarter followed a predictable seasonal pattern: Q3 dips slightly versus Q2 as export markets close mid-December for holidays, but remains well above Q1 levels.
• Profitability compounding faster than revenue: EBITDA grew 37% YoY in Q3 and 47% YoY in 9M, while adjusted PAT rose ~84% YoY for the nine-month period. Return on equity sits around 20%.
• Margin engine is structural, not cyclical: The company has now delivered 20%-plus EBITDA margins for 10 consecutive quarters, with the last three near 25%. Levers include improving process yields (more output from same input), reducing utility consumption through steam conservation and residual heat recovery at scale, and solar power lowering energy costs. A dedicated senior-led department works on this continuously.
• Gross margin can still inch up, but not forever: Management estimates another 100-200 basis points of gross margin improvement is achievable, though the gains cannot be perpetual.
• Forex tailwind: As a net exporter, the company benefits from rupee depreciation; Q3 forex income was INR3.5 crores.
• State incentive recognition is annual, not quarterly: No incentive was booked in Q3. For the nine-month period, approximately INR10 crores was taken in revenue. An upgrade to ultra mega status (total investment exceeding INR1,500 crores by 31 March 2027) would extend the full 9% GST benefit to 20 years from the current 15, with the benefit doubling for sales within Maharashtra.

Babani: "We want to be a little cautious on telling you 25% for sure, but it will be upwards of 20% and less than 27%. It will be somewhere in between."

Capacity Expansion & the INR5,000 Crore Roadmap

• Three-phase build, fully funded: Total capex of INR1,200 crores over three years: Phase 1 at INR300 crores, Phase 2 at INR600 crores, Phase 3 at INR300 crores. All spending completes by March FY28, with the INR5,000 crore revenue and INR1,000 crore-plus EBITDA target achievable by FY29. No equity dilution is needed; internal accruals and bank borrowing suffice.
• Phase 1 imminent: Capacity rises from 48,000 to 54,000 metric tons for existing products, with commercialization expected by end-March, latest April '26. Management expects to maintain roughly 90% capacity utilization on the expanded base for March '27.
• Phase 2 is the heavy lift: The multi-speciality project carries the bulk of the capex and is expected to complete by Q1 of next financial year.
• Phase 3 and the transition year: The new product facility comes on stream sometime in Q1 FY28. FY28 is explicitly flagged as a transition year; FY29 is when revenue growth scales materially.
• Debt guardrails: Debt-to-EBITDA will be maintained below 2.5x; the current ratio is approximately 1.6x.

Patil: "2029 will be the year where there will be -- we will catapult into the next level of revenues and growth and everything."

Prigiv Joint Venture: Inflection Point

• Positive EBITDA achieved: The JV with Givaudan turned EBITDA-positive in Q3 FY26, a milestone after the earlier debt burden weighed on performance.
• Balance sheet repair underway: Givaudan agreed to provide a noninterest-bearing trade advance to reduce Prigiv's debt, thereby cutting interest cost. The INR150 crore advance will be adjusted over a long-term period of 10 years, possibly stretched to 15.
• Fresh equity for new products: An equity infusion of INR50 crores is planned (Privi 51%, Givaudan 49%) to create capacity for additional molecules. Privi's team is already scaling up a medium-sized speciality molecule for Prigiv, with development costs funded by the JV.
• Profitability next year: Management expects Prigiv to achieve net profit in the coming financial year. Critically, revenue from the JV is additional to the standalone INR5,000 crore, INR1,000 crore EBITDA target.

Patil: "Privi management convinced the joint venture partner, Givaudan, that the debt burden on Prigiv needs to be reduced."

New Molecules & Bio-Route Technology

• Cyclopentanone via bio-route: The molecule will be manufactured for the first time using a renewable raw material through a biological process. Current capacity is only 500 tons; a scale-up to 5,000 tons is targeted within two years.
• The 10,000 story: Management intends to announce a further scale-up to 10,000 tons before the 5,000-ton milestone is even reached. A second molecule from a similar raw material base has already been developed and will go through 1-2 years of lab trials, then 6-12 months of piloting, before engineering and launch.
• Corn cob project progressing at lab scale: Processing is currently at the kilogram level, with data being assembled to create intellectual property and patents. A demonstration facility is planned over the next 12-18 months, followed by a pilot facility, then full scale. Management is "100% confident" of scaling to lab or commercial level by end of 2027, but will launch the project only in 2028, at a 20,000-ton level.
• Furfural backward integration: In-house production of Furfural is planned as the next project after the current expansion cycle completes.
• Technology licensing optionality: The company could franchise or license its biomass-based technologies to different parts of the world in coming years.

Babani: "Technology is developed pretty well. We are confident of scaling up, but we can't bite more than can we chew. So we are biting what we can chew right now."

Competitive Position & Trade Advantages

• Structural duty advantage over China: An 18% duty is confirmed for the company's product range, with some products at 0%. The EU trade treaty and the US lifting of the 25% tariff provide additional thrust to growth plans.
• CBAM tailwind deferred, not dead: Carbon border adjustment mechanism advantages (6-9% duty-free versus other countries) have taken a back seat due to geopolitical disturbances, but management expects them to materialize in the next 2-3 years as carbon footprint differentiation regains focus. Within one year, CBAM is expected to "bounce back." Clarity is still needed on whether Switzerland participates.
• Product development discipline: New products must carry EBITDA north of 20%, with a target of 22-24% even for products starting at 18%, achieved through technology improvement and catalyst use.

Babani: "Today, of late because of geopolitical disturbances, this has taken a back seat. But in the next 2 to 3 years, I can assure you with carbon footprint like ours, there will be duty advantages."

Corporate Actions & Structure

• Three-way amalgamation in process: The merger of Privi Fine Sciences Private Limited and Privi Biotechnologies Limited into Privi Speciality Chemicals Limited is underway. All necessary data and filings have been submitted to both stock exchanges. The NCLT order is expected by October '26 if expedited, latest by December '26, with merged numbers definitely available by FY27.
• Promoter share sale for liquidity: Promoters sold some shares to a "very reputed investor" (described as the country's largest) to improve market conditions and liquidity. Some leakages disturbed the market. Promoter holding remains at 63%. The investor name and exact quantity sold were not disclosed.

Babani: "In coming times, our story is not only 5,000. It will become -- in coming times before we reach 5,000, we'll announce the 10,000 story also."

Guidance & Commitments

Key Metrics